| Primary |
| Multiple Myeloma |
33.0% |
| Prophylaxis |
11.1% |
| Prostate Cancer |
10.9% |
| Hypertension |
9.2% |
| Thrombosis Prophylaxis |
8.1% |
| Constipation |
3.8% |
| Pain |
3.8% |
| Infection Prophylaxis |
2.2% |
| Hodgkin's Disease |
1.9% |
| Bone Pain |
1.7% |
| Back Pain |
1.7% |
| Rash |
1.7% |
| Supplementation Therapy |
1.6% |
| Myelodysplastic Syndrome |
1.6% |
| Insomnia |
1.5% |
| Mantle Cell Lymphoma |
1.4% |
| Nausea |
1.4% |
| Product Used For Unknown Indication |
1.3% |
| Acute Myeloid Leukaemia |
1.1% |
| Atrial Fibrillation |
1.1% |
|
| Pneumonia |
10.5% |
| Squamous Cell Carcinoma Of Skin |
7.4% |
| Acute Myeloid Leukaemia |
6.2% |
| Death |
5.9% |
| Sepsis |
5.5% |
| Basal Cell Carcinoma |
5.2% |
| Prostate Cancer |
5.2% |
| Pulmonary Embolism |
5.2% |
| Pyrexia |
5.2% |
| Neutropenia |
5.0% |
| Pancytopenia |
5.0% |
| Renal Failure Acute |
4.8% |
| Myelodysplastic Syndrome |
4.5% |
| Anaemia |
3.8% |
| Breast Cancer |
3.8% |
| General Physical Health Deterioration |
3.8% |
| Vomiting |
3.6% |
| Febrile Neutropenia |
3.3% |
| Multiple Myeloma |
3.1% |
| Platelet Count Decreased |
3.1% |
|
| Secondary |
| Multiple Myeloma |
34.9% |
| Product Used For Unknown Indication |
11.5% |
| Prophylaxis |
7.6% |
| Thrombosis Prophylaxis |
6.7% |
| Plasma Cell Myeloma |
5.1% |
| Hypertension |
4.8% |
| Prostate Cancer |
4.5% |
| B-cell Lymphoma |
4.4% |
| Chronic Lymphocytic Leukaemia |
2.5% |
| Mantle Cell Lymphoma |
2.5% |
| Constipation |
2.4% |
| Pain |
2.1% |
| Diffuse Large B-cell Lymphoma |
1.6% |
| Back Pain |
1.5% |
| Drug Use For Unknown Indication |
1.5% |
| Infection Prophylaxis |
1.5% |
| Bone Pain |
1.4% |
| Amyloidosis |
1.3% |
| Myelodysplastic Syndrome |
1.1% |
| Rash |
1.0% |
|
| Pneumonia |
10.9% |
| Thrombocytopenia |
8.6% |
| Neutropenia |
7.5% |
| Pyrexia |
7.1% |
| Sepsis |
6.8% |
| Pulmonary Embolism |
5.8% |
| Deep Vein Thrombosis |
5.4% |
| Renal Failure Acute |
4.8% |
| Acute Myeloid Leukaemia |
4.5% |
| Basal Cell Carcinoma |
4.3% |
| Death |
4.3% |
| Squamous Cell Carcinoma Of Skin |
4.3% |
| Syncope |
3.8% |
| Dyspnoea |
3.7% |
| Renal Failure |
3.5% |
| Myelodysplastic Syndrome |
3.4% |
| Prostate Cancer |
3.4% |
| Febrile Neutropenia |
2.9% |
| Vomiting |
2.6% |
| Diarrhoea |
2.3% |
|
| Concomitant |
| Multiple Myeloma |
38.2% |
| Plasma Cell Myeloma |
13.6% |
| Product Used For Unknown Indication |
9.2% |
| Chronic Lymphocytic Leukaemia |
6.9% |
| Lymphoma |
6.6% |
| Myelodysplastic Syndrome |
3.6% |
| Prophylaxis |
3.4% |
| Idiopathic Thrombocytopenic Purpura |
2.8% |
| Back Pain |
1.9% |
| Chemotherapy |
1.6% |
| Neoplasm Malignant |
1.4% |
| Premedication |
1.4% |
| Sleep Disorder |
1.4% |
| Hodgkin's Disease |
1.3% |
| Lung Neoplasm Malignant |
1.3% |
| Infection Prophylaxis |
1.1% |
| Iron Overload |
1.1% |
| Nausea |
1.1% |
| Non-hodgkin's Lymphoma |
1.1% |
| Pain |
1.1% |
|
| Weight Decreased |
14.9% |
| Wound Drainage |
14.9% |
| Thrombocytopenia |
6.6% |
| Paraesthesia |
5.8% |
| Progressive Multifocal Leukoencephalopathy |
5.8% |
| Upper Respiratory Tract Infection |
5.8% |
| Vision Blurred |
5.8% |
| Myelodysplastic Syndrome |
5.0% |
| Osteonecrosis Of Jaw |
5.0% |
| Anaemia |
3.3% |
| Death |
3.3% |
| Neuropathy Peripheral |
3.3% |
| Urinary Retention |
3.3% |
| Abdominal Pain |
2.5% |
| Fatigue |
2.5% |
| Febrile Neutropenia |
2.5% |
| Hepatitis B |
2.5% |
| Liver Function Test Abnormal |
2.5% |
| Night Sweats |
2.5% |
| Osteonecrosis |
2.5% |
|
| Interacting |
| Multiple Myeloma |
34.4% |
| Infection Prophylaxis |
25.0% |
| Polyneuropathy |
14.6% |
| Plasma Cell Myeloma |
9.4% |
| Antifungal Prophylaxis |
8.3% |
| Chest Pain |
2.1% |
| Disease Progression |
2.1% |
| Hypertension |
1.0% |
| Myelodysplastic Syndrome |
1.0% |
| Prophylaxis |
1.0% |
| Thrombosis Prophylaxis |
1.0% |
|
| Drug Level Increased |
27.6% |
| Rhabdomyolysis |
24.1% |
| Drug Ineffective |
13.8% |
| Drug Interaction |
13.8% |
| Tetany |
6.9% |
| Inappropriate Antidiuretic Hormone Secretion |
3.4% |
| Rash Generalised |
3.4% |
| Supraventricular Extrasystoles |
3.4% |
| Venous Thrombosis |
3.4% |
|
